(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 6.01% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 5.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.91%.
Amneal Pharmaceuticals's revenue in 2025 is $2,852,914,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $947,043,340,428, with the lowest AMRX revenue forecast at $942,099,732,104, and the highest AMRX revenue forecast at $952,143,988,406. On average, 3 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,003,924,045,526, with the lowest AMRX revenue forecast at $985,769,319,227, and the highest AMRX revenue forecast at $1,027,796,271,565.
In 2027, AMRX is forecast to generate $1,071,041,851,621 in revenue, with the lowest revenue forecast at $1,028,452,697,321 and the highest revenue forecast at $1,113,631,005,921.